Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex for post-herpetic neuralgia (PHN) symptom relief
2006-003655-20Phase 3Terminated
- Sponsor
- GW Pharmaceuticals
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postherpetic neuralgia (PHN) comparing Sativex add-on arm with Placebo add-on arm (2 arms). Primary endpoint: Change in mean pain NRS score from baseline to end of treatment. Started Nov 2006; status: terminated.
02
Drugs
cannabidiol
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on 2006-003655-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003655-20.